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A human thyroid peroxidase eDNA, hTPO-1 [(1987) Proe. Natl. Aead. Sei. USA 84, 5555-5559], was expressed inhuman 
Hep G2 cells using a vaccinia virus eDNA-expression system. When examined by immunoblot analysis, the level of 
hTPO-1 protein expression reached a maximum approx. 24 h after infection and remained at a similar level up to 72 h 
post-infection. The expressed protein was enzymatieally active as measured by guaiacol oxidation. Monoclonal antibody- 
assisted immunoaffinity column chromatography was used for partial purification of vaceinia-expressed hTPO-I, result- 
ing in more than 300-fold higher specific activity and a measurable difference spectrum of the hTPO-1 (Fea+)-CN com- 
plex. 
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1. INTRODUCTION 
Thyro id  peroxidase (TPO; donor :hydrogen-  
peroxide oxidoreductase,  EC 1.11.1.7) is one of  
the key enzymes involved in the biosynthesis of  
thyro id  hormones.  It catalyzes both iodinat ion and 
coupl ing of  tyrosine residues in thyroglobul in  to 
produce thyroxine (T4) and t r i iodothyronine (T3) 
[1,2]. The enzyme is a glycosylated hemoprote in  
[3] o f  about  107 kDa as est imated on SDS- 
po lyacry lamide gels [4-8].  The prosthet ic group is 
p robab ly  protoporphyr in  IX [1,8,9]. Several 
reports have establ ished that TPO is a ma jor  com- 
ponent  of  the thyro id microsomal  antigen, one of  
the auto immune antigens against which patients 
having thyro id auto immune disorders develop an- 
t ibodies [4,10-12]. 
The human TPO cDNA has recently been cloned 
and its nucleotide and deduced amino acid se- 
quences determined [12-15]. '  The hTPO-1 eDNA 
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we isolated is 3048 nucleotides in length and codes 
for a protein with 933 amino acids [13]. Here, we 
describe, for the first t ime, expression of  the 
human TPO cDNA (hTPO-1) using a vaecinia- 
virus expression system. This expressed protein 
was highly active as measured by guaiacol  oxida- 
t ion after enr ichment through an immunoaf f in i ty  
co lumn.  
2. MATERIALS  AND METHODS 
Human TPO eDNA, hTPO-1, used here was constructed by 
joining phTPO-2.8 to phTPO-5' at a BgllI ske (435-460 bp in 
[13]). Human TPO was purified as in [8] and rabbit anti- 
porcine TPO antibody has been produced [11]. Phosphatase- 
conjugated goat anti-rabbit IgG antibody was purchased from 
KPL Laboratories (Gaithersburg, MD). Vaccinia virus (strain 
WR), recombinant vector pSC11 and human TK- 143 cells were 
obtained from Dr Bernard Moss (National Institute of Allergy 
and Infectious Diseases). CV-1 (ATCC CCL 70) and Hep G2 
(ATCC HB 8065) cells were from the American Type Culture 
Collection. 
The vaceinia virus expression system was used to express full- 
length TPO-I eDNA. The insert was first made blunt-ended by 
DNA polymerase Klenow fragment and ligated to the 
dephosphorylated SmaI site of recombinant plasmid pSCI1 
[16]. The plasmid containing hTPO-1, or no insert as control, 
was then allowed to be integrated into vaccinia virus according 
to [ 16,17]. Briefly, CV- 1 cells were infected with wild-type vac- 
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cinia virus prior to transfection with calcium phosphate 
precipitates of vaccinia virus DNA and recombinant plasmid 
pSC11 containing cDNA insert or no insert. Virus particles were 
harvested after 2 days and recombinant virus selection was in- 
itiated by infecting human TK- cells with the harvested viruses 
in the presence of 5-hromodeoxyuridine (BudR). The basis for 
this selection isas follows: plasmid pSCll has portions of the 
thymidine kinase (TK) sequences that flank vaccinia virus pro- 
moters and the Sinai cloning site. Recombination takes place 
between TK sequences in the vector and those in the wild-type 
virus genome, producing recombinant viruses which are no 
longer capable of synthesizing ative TK protein due to disrup- 
tion of the TK gene by plasmid insertion. Only viruses without 
an active TK gene can survive in the presence ofBudR. In order 
to distinguish recombinant viruses from those having spon- 
taneous mutations in their TK gene, expression of ~he B- 
galactosidase g ne, which occurs in the pSCI1 plasmid, was 
also used for selection. After three successive BudR and B- 
gaiactosidase lections, vaccinia virus producing hTPO-1, 
designated vhTPO-1, was identified by immunoblotting using 
rabbit anti-porcine TPO antibody. 
Hep G2 cells infected by vhTPO-1 were harvested in 
phosphate-buffered saline (pH 7.2) at various times after infec- 
tion as indicated, and sonicated for 5 s. Cell lysates thus obtain- 
ed were then directly subjected to SDS-polyacrylamide g l
electrophoresis (100/~g protein/well) [18]. Blotting was per- 
formed using a semi-dry blotter (Integrated Separation 
Systems, Hyde Park, MA) via the method of Kyhse-Andersen 
[19]. After treatment with antibodies, final color development 
of the alkaline phosphatase r action was carried out using 
5-bromo-4-chloro-3-indolyl phosphate and nitroblue 
tetrazolium as substrates (KPL Laboratories). Protein concen- 
tration was determined using BCA protein assay reagent 
(Pierce, Rockford, IL). 
Immunopuriflcation f the expressed hTPO-I protein was 
carried out by means of immunoafflnity column 
chromatography using monoclonai antibody 38E to human 
TPO as described [8]. Briefly, Hep G2 ceils, harvested after ap- 
prox. 50 h post-infection, were homogenized in 20 mM Tris 
buffer, pH 7.4, containing 0.2% sodium cholate, 0.1 M KCI, 
and 0.1 mM KI. After sedimentation f cell debris, the superna- 
tant was directly applied onto a column of Sepharose 4B cou- 
pled with monoclonal antibody 38E [8]. The column was 
washed with 50 mM borate buffer, pH 9.0, containing 0.5% 
sodium cholate, 1 M KCl and 1 mM KI. The expressed hTPO-1 
was eluted with 0.2 M NH4OH containing 0.5% sodium 
cholate, 1 M KC1, and 1 mM KI [8]. Peak fractions were com- 
bined, then concentrated and desalted using Centricon 30 
(Amicon, Danvers, MA) in 20 mM Tris buffer (pH 7.4), con- 
taining 0.1 mM KI. 
TPO activity was determined in 0.1 M Tris (pH 7.4) at 20°C 
by using guaiacol oxidation on an Aminco DW-2000 spec- 
trophotometer. Guaiacol oxidation was measured by following 
the absorbance change at 470 nm in the presence of 30 mM 
guaiacol and 0.5 mM H202. 
3. RESULTS AND DISCUSSION 
The recombinant virus, vhTPO-1,  obtained as 
outl ined in section 2, was used to infect Hep G2 
cells. The human hepatoma Hep G2 cell line was 
chosen to express hTPO-1 in this study, since this 
liver-derived cell line is known to possess ample in- 
tracellular membranes and to express a variety of 
heme proteins, therefore containing sufficient 
heme. Cells were harvested at various times after 
infection as indicated, subjected to immunoblot -  
ting, and found to possess hTPO-1 protein (fig. 1). 
The size of the expressed protein is the same as that 
of the purified protein (about 107 kDa) [4,8,11]. 
Expressed hTPO-1 appeared as early as 6 h after 
infection (not shown) and the level of  synthesis 
reached a maximum approx. 24 h after infection 
(f ig. l).  The level of expressed protein remained 
elevated up to 72 h post-infection, suggesting that 
the hTPO-1 expressed protein is not particularly 
labile. Based on the immunoblot  band intensity 
and comparisons with purif ied TPO,  the amount  
of hTPO-1 expressed protein was estimated to be 
about  0.3-0.6/~g/100/~g cell lysate. 
Peroxidase activity was determined by guaiacol 
oxidation using a cell lysate expressing hTPO-1 
proteins (table 1). Ceils harvested 48 h after infec- 
t ion with either wild-type vaccinia virus or recom- 
b inant  virus containing plasmid pSC l l  only 
displayed no activity. These results indicate that 
measurable peroxidase activity was indeed derived 
from the cDNA-expressed hTPO-1. The activity 
was detected in 24 h post- infection cells and reach- 
h 
Fig.l. Immunoblot analysis of vaccinia virus-expressed 
hTPO-I, vhTPO-1 infected Hep G2 cells were harvested at 
various post-infection times as indicated (11, 24, 48, 72 h). 
Wild-type vaccinia infected cells (vWT) were harvested 48 h 
after infection. Cells were processed as described in section 2 
and 100/~g protein of the cell lysate was loaded per lane. The 
same results as those for vWT were obtained by using vaccinia 
virus carrying plasmid pSCI1. A dilution series of purified 
human TPO (0.2, 0.4/~g) was electrophoresed on the same gel 
to estimate the amount of expressed hTPO-1 protein. 
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Table 1 
Guaiacol oxidation activity of vaccinia virus-expressed hTPO-1 
protein 
Post-infection time (h) Guaiacol oxidation activity 
vWT (48) ND 
vhTPO-1 (11) ND 
(24) 0.032 _+ 0.001 
(48) 0.181 + 0.006 
(72) 0.256 + 0.004 
hTPO-1 after immunoaffinity 
column 80.8 _+ 2.3 
Guaiacol oxidation activity was measured asdescribed in the 
text. Values represent the specific activity expressed in 
AA47o/min per mg protein. ND, no detectable activity. Activity 
determination was performed atleast hree times per sample 
and values are means + SD 
ed maximal evel at 72 h (table 1). No measurable 
activity was observed in the 11 h sample. These 
data are interesting because the level of im- 
munodetectable hTPO-1 protein in 11 h post- 
infection cells was at least 1/4 that of maximally 
expressed proteins obtained in the 24-72 h post- 
infection cells (fig. 1). These results indicate the ex- 
istence of a lag time ( -24 h) between expressed 
protein level and activity expression (fig.1 and 
table 1). This may be due to post-translational 
modification of the protein, which is a necessary 
requirement for activity. Potential post- 
translational modifications might be glycosylation 
or signal peptide cleavage. The presence of signal 
peptide at the N-terminus of TPO has been 
predicted based on the cDNA-deduced amino acid 
sequence [12,13,15]. It might be expected that 
changes in glycosylation or signal peptide cleavage 
would be detectable from differences in mobility 
on SDS-polyacrylamide g ls, however, no obvious 
differences are seen in the inactive protein present 
at 11 h post-infection and the most active protein 
present at 72h  (fig.l). The pertinent post- 
translational modification might be too subtle for 
detection on gels. Another possibility that could 
account for the lag time in activity is that heme in- 
corporation does not occur during or soon after 
protein synthesis. 
The Hep G2 cell lysate after solubilization with 
sodium cholate [8] was further subjected to partial 
purification of hTPO-1 protein using monoclonal 
antibody to human TPO [8] as described in section 
R 
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Fig.2. Difference spectrum of expressed hTPO-l(Fe3÷)-cyanide 
complex. Solutions containing enriched hTPO-1 ( ) or 
control protein ( - - - )  were divided into two cuvettes. Non- 
specific proteins that were eluted from an immunoaffinity 
column with the same buffer as for eluting hTPO-1 were 
prepared using Hep G2 cells infected with wild-type vaccinia 
virus and were used as control protein. A crystal of KCN was 
then added to a sample cuvette and the difference spectrum 
recorded on an Aminco DW-2000 spectrophotometer. 
2. The partially purified hTPO-1 exhibited a dif- 
ference spectrum, when complexed with cyanide, 
with )~m~ at 433 nm (fig.2). This is similar to that 
reported in [20] and clearly indicates that the ex- 
pressed hTPO-1 is a heme-protein. After immu- 
noenrichment, the hTPO-1 exhibited greater than 
300-fold higher specific activity as measured by 
guaiacol oxidation (table 1). This is the first report 
describing the production of an enzymatically ac- 
tive cDNA-expressed mammalian peroxidase. Fur- 
ther studies using site-directed mutagenesis should 
help in gaining insights into the structure-function 
relationships of these peroxidases. 
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